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“arbitrary assumptions on model parameters like the of follow-up. From one 10-year-old reference is the mes-
sage that “routine measurement of vitamin B12 concentra-glomerular transmembrane hydraulic pressure and the
tions and inclusion of vitamin B12 in the supplementsultrafiltration coefficient” is uncorrect since the theoreti-
should completely eliminate . . . the risk of masking vita-cal model depends only on one assumed parameter, the
min B12 deficiency.” Because close surveillance is sug-glomerular transmembrane pressure. Assuming this pa-
gested to look for adverse effects produced from folaterameter, the value of the ultrafiltration coefficient is con-
fortification of food in the general population, which in-sequently derived. In addition, we and others have shown
creases serum folate from 10.8 to 19.0 ng/mL [2], how canthat the influence of the glomerular transmembrane pres-
we forecast that in uremic people values as high as 200sure on the calculated shunt parameter omega is negligi-
to 400 ng/mL are safe over a long time? Treatment forble [5, 6]. Thus, the criticism that no unique model can
hyperhomocysteinemia in uremic patients results in nor-be identified is not appropriate.
mal vitamin B12 coupled with very high folate concen-
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Monitoring side effects in thousands of patients receiv-
To the Editor: The excellent paper by De Vriese et al ing 0.4 to 4,0 mg folate and in smaller numbers taking
in a recent issue of Kidney International on folate for large doses for several years has revealed no evidence for
cardiovascular disease in uremia largely underestimates toxicity [1, 2]. In renal failure patients, no side effects
the risk of folate overdose [1]. The suggestion that “high have been reported so far, the longest follow-up being 17
doses of folic acid are well tolerated and safe” takes root months.
Concerns about large-scale folate administration gener-from four studies with 4 to 8 weeks and 12 to 17 months
